sponsored
PatientsVille.com Logo

PatientsVille

Injection Site Induration Medical Research Studies

Up-to-date List of Injection Site Induration Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Injection Site Induration Medical Research Studies

Rank Status Study
1 Recruiting Neurogenic Inflammation in Diabetes
Conditions: Diabetes Mellitus;   Polyneuropathies;   Arthropathy, Neurogenic
Interventions: Other: Intracutaneous injection of Candida albicans antigen.;   Procedure: Punch skin biopsy;   Other: Temperature measurement.
Outcome Measures: Induration size as a response to intracutaneous Candida albicans.;   Temperature at the injection site of the highest concentration of Candida albicans antigen on the foot, compared to the same location on the contralateral foot.;   Nature of the induration that appears as a response to intracutaneous Candida albicans evaluated by microscopy of a skin biopsy taken at the injection site of the highest concentration of Candida albicans on the foot.
2 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
3 Recruiting Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Condition: Bipolar I
Intervention: Drug: Aripiprazole
Outcome Measures: Number and percentage of subjects with adverse events;   Injection Site Pain measured by the Visual Analog Scale (VAS);   Number and percentage of subjects with clinically significant abnormal laboratory test results, vitals, ECGs;   Extrapyramidal Symptoms (EPS) will be assessed by change from baseline on Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS used in Japan), and Barnes Akathisia Rating Scale (BARS);   Assessment of risk of suicidal events and classification by completion of C-SSRS;   Injection Site Evaluations (pain, redness, swelling, induration) measured by investigator rating;   Percentage of subjects who remain stable at end of treatment in Phase C
4 Recruiting Immunotherapy in Subjects With HPV6 (Human Papillomavirus) Associated Aerodigestive Malignancies
Condition: Aerodigestive Malignancies (e.g Squamous Cell Carcinoma)
Intervention: Biological: INO-3106, INO-9012
Outcome Measures: Adverse events measured and graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03;   Injection site reactions including skin erythema, induration pain and tenderness at administration site;   HPV6 specific Ig levels;   Number of antigen-specific IFN-γ-secreting cells in response to stimulation with HPV6 by antigen-specific IFN-γ ELISpot assays;   Cytotoxic T cells in response to HPV6 specific immunotherapy by flow cytometry
5 Recruiting Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers
Conditions: Breast Cancer;   Lung Cancer;   Pancreatic Cancer
Interventions: Biological: INO-1400;   Biological: INO-9012
Outcome Measures: Adverse events graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03;   Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration site [;   Changes in safety laboratory parameters from baseline;   Time to progression;   Antigen specific cellular immune responses;   Antigen specific ELISA;   H&E stain; immunohistochemistry for CD45, CD3, CD8, FoxP3; and TCRbeta molecular analysis of baseline/archival tumor tissue and relapsed tumor tissue, when possible.
6 Recruiting An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease
Condition: Peyronie's Disease
Interventions: Biological: AA4500;   Device: ErecAid® Esteem® Manual Vacuum Therapy System;   Procedure: Investigator Modeling
Outcome Measures: Percent in improvement from baseline in penile curvature;   Change in Peyronies disease bother;   Change in Peyronies disease physical symptoms;   Change in Peyronies disease psychological symptoms;   Change in penile plaque consistency;   Change in penile length;   Change in Peyronies disease penile pain;   A responder analysis based on subject global assessment

These studies may lead to new treatments and are adding insight into Injection Site Induration etiology and treatment.

A major focus of Injection Site Induration research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Injection Site Induration